Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Operating Leases (2019 - 2026)

Corcept Therapeutics (CORT) has disclosed Operating Leases for 7 consecutive years, with $8.0 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases rose 17.19% year-over-year to $8.0 million; the TTM value through Mar 2026 reached $8.0 million, up 17.19%, while the annual FY2025 figure was $5.0 million, 17.75% down from the prior year.
  • Operating Leases hit $8.0 million in Q1 2026 for Corcept Therapeutics, up from $5.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.0 million in Q1 2026 and bottomed at $76000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $3.6 million, with a median of $3.9 million recorded in 2022.
  • Year-over-year, Operating Leases tumbled 86.88% in 2023 and then surged 8893.42% in 2025.
  • Corcept Therapeutics' Operating Leases stood at $1.1 million in 2022, then crashed by 80.31% to $225000.0 in 2023, then soared by 2614.22% to $6.1 million in 2024, then fell by 17.75% to $5.0 million in 2025, then skyrocketed by 59.47% to $8.0 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $8.0 million, $5.0 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.